PD-1/PD-L1在dMMR/MSI-H结直肠癌患者临床试验中的研究进展

Progression of the research on PD-1/PD-L1 in dM MR/MSI-H colorectal cancer

结直肠癌是目前常见的肿瘤之一,关于DNA错配修复缺陷(dM MR)/微卫星高频不稳定(MSI-H)结直肠癌PD-1/PD-L1免疫疗法是目前关注的热点,多项临床试验已取得良好的疗效,2017年NCCN指南更新推荐纳武单抗(nivolumab)和派姆单抗(pembrolizumab)作为dM MR/MSI-H转移性结直肠癌二线或三线的药物选择。本文对当前dM MR/MSI-H结直肠癌特点、PD-1/PD-L1生物学功能、PD-1/PD-L1在结直肠癌中的治疗以及研究过程中出现的严重不良反应方面的研究进展作一综述。

At present,colorectal cancer is one of the common tumors,and PD-1/PD-L1 immunotherapy for dMMR/MSI-H colorectal cancer is a hot spot.Some clinical trials have achieved good results.In 2017,NCCN guide recommends nivolumab and pembrolizumab as the drug choice for the second or third line of dMMR/MSI-H metastatic colorectal cancer.In this paper,the present study on the characteristics of dMMR/MSI-H colorectal cancer,the biological function of PD-1/PD-L1,the treatment of PD-1/PD-L1 in CRC and the serious adverse reactions in the research process were reviewed.